Stock Events

Stock Events

IGM Biosciences

€10.90

0

+€1.75+19.13% Tuesday 20:00

Statistics

Day High

-

Day Low

-

52W High

16.3

52W Low

0.865

Volume

-

Avg. Volume

0

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biotechnology field, focusing on immunotherapy treatments which overlap with IGM Biosciences' work on antibody therapeutics.

Amgen is a biotech firm that develops innovative human therapeutics, including in the immunology space, making it a direct competitor to IGM Biosciences.

Gilead Sciences

Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas including immunology, directly competing with IGM Biosciences.

Biogen focuses on discovering, developing, and delivering worldwide innovative therapies for people living with serious neurological diseases, competing indirectly with IGM Biosciences in the broader biotech space.

Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals, including immunotherapy treatments, competing with IGM Biosciences in the immunology and oncology sectors.

Roche Holding AG engages in the pharmaceuticals and diagnostics business, focusing on oncology, immunology, and infectious diseases, areas where IGM Biosciences is also active.

AstraZeneca operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of prescription medicines, including in areas that compete with IGM Biosciences' focus.

Pfizer is a global biopharmaceutical company with a broad range of products in oncology, immunology, and other areas, making it a competitor to IGM Biosciences.

Novartis focuses on patented medicines, generics, and biosimilars, with a strong presence in immunology and oncology, competing with IGM Biosciences.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose areas of research include cancer, immunology, and cardiovascular diseases, competing with IGM Biosciences in the development of innovative therapies.

About

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Show more...

CEO

Ms. Mary Beth Harler M.D.

Employees

16

Country

United States

ISIN

US4495851085

WKN

000A2PPQK

Listings

0 Comments

Share your thoughts

FAQ

What is IGM Biosciences stock price today?▼

The current price of 1K0.STU is €10.90 EUR — it has increased by +19.13% in the past 24 hours. Watch IGM Biosciences stock price performance more closely on the chart.

What is IGM Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange IGM Biosciences stocks are traded under the ticker 1K0.STU.

How many employees does IGM Biosciences have?▼

As of September 04, 2026, the company has 16 employees.

In which sector is IGM Biosciences located?▼

IGM Biosciences operates in the Health & Wellness sector.

When did IGM Biosciences complete a stock split?▼

IGM Biosciences has not had any recent stock splits.

Where is IGM Biosciences headquartered?▼

IGM Biosciences is headquartered in Mountain View, United States.